title: Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment.
abstract: Tuberculosis risk is increased in patients with chronic inflammatory diseases receiving any immunosuppressive treatment, notably tumor necrosis factor (TNF) antagonists therapy. Screening for the presence of latent infection with Mycobacterium tuberculosis and targeted preventive treatment to reduce the risk of progression to TB is mandatory in these patients. This Consensus Document summarizes the current knowledge and expert opinion of biologic therapies including TNF-blocking treatments. It provides recommendations for the use of interferon-gamma release assays (IGRA) and tuberculin skin test (TST) for the diagnosis of latent tuberculosis infection in these patients, and for the type and duration of preventive therapy.
authors.affiliation: Servicio de Neumología, Hospital Son Llàtzer, Palma de Mallorca, España. Electronic address: imir@hsll.es.
authors.forename: Isabel
authors.initials: I
authors.lastname: Mir Viladrich
authors.affiliation: Servicio de Dermatología, Hospital Universitario de la Princesa, Madrid, España.
authors.forename: Esteban
authors.initials: E
authors.lastname: Daudén Tello
authors.affiliation: Servicio de Dermatología, Hospital Universitario de la Princesa, Madrid, España.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Solano-López
authors.affiliation: Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, España.
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: López Longo
authors.affiliation: Servicio Aparato Digestivo, Hospital Clínico San Carlos e Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Madrid, España.
authors.forename: Carlos
authors.initials: C
authors.lastname: Taxonera Samso
authors.affiliation: Servicio de Enfermedades Infecciosas, Hospital del Mar, Barcelona, España.
authors.forename: Paquita
authors.initials: P
authors.lastname: Sánchez Martínez
authors.affiliation: Unidad control de Tuberculosis, Hospital Universitari Mútua de Terrassa, Terrassa, Barcelona, España.
authors.forename: Xavier
authors.initials: X
authors.lastname: Martínez Lacasa
authors.affiliation: Servicio de Medicina Interna, Unidad de Enfermedades Infecciosas, Hospital Son Llàtzer, Palma de Mallorca, España.
authors.forename: Mercedes
authors.initials: M
authors.lastname: García Gasalla
authors.affiliation: Servicio de Neumología, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, España.
authors.forename: Jordi
authors.initials: J
authors.lastname: Dorca Sargatal
authors.affiliation: Servicio de Neumología, Hospital Universitario Central de Asturias-Instituto Nacional de Silicosis, Oviedo, Asturias, España.
authors.forename: Miguel
authors.initials: M
authors.lastname: Arias-Guillén
authors.affiliation: Servicio de Neumología, Hospital San Agustín, Avilés, Asturias, España.
authors.forename: José Maria
authors.initials: JM
authors.lastname: García García
mesh_terms: D001691:Biological Therapy; D006801:Humans; D007165:Immunosuppression Therapy; D055985:Latent Tuberculosis / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy*; D017410:Practice Guidelines as Topic
keywords: Biologic therapies; Chronic inflammatory diseases; Enfermedades inflamatorias crónicas; Infección tuberculosa latente; Interferon-gamma release assays; Latent tuberculosis infection; Terapias biológicas; Técnicas de liberación de interferón gamma